Modulation of genomic and epigenetic end-points by celecoxib

Celecoxib, a nonsteroidal anti-inflammatory drug that selectively targets cyclooxygenase-2, is a promising cancer chemopreventive agent. However, safety concerns have been raised in clinical trials evaluating its ability to prevent colorectal adenomas. The rationale for the herein reported studies w...

Descripción completa

Detalles Bibliográficos
Autores principales: Izzotti, Alberto, La Maestra, Sebastiano, Micale, Rosanna T., Pulliero, Alessandra, Geretto, Marta, Balansky, Roumen, De Flora, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154745/
https://www.ncbi.nlm.nih.gov/pubmed/30263093
http://dx.doi.org/10.18632/oncotarget.26062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154745/
https://www.ncbi.nlm.nih.gov/pubmed/30263093
http://dx.doi.org/10.18632/oncotarget.26062

Ejemplares similares